Novo Nordisk A/SNVONYSE
Loading
Gross Profit Over TimeStrong
Percentile Rank93
3Y CAGR+17.2%
5Y CAGR+17.6%
Studio
Year-over-Year Change

Revenue minus cost of goods sold

3Y CAGR
+17.2%/yr
vs +12.0%/yr prior
5Y CAGR
+17.6%/yr
Consistent
Acceleration
+5.1pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.3x
Strong expansion
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
2025$238.77B-2.9%
2024$245.88B+25.1%
2023$196.50B+32.3%
2022$148.51B+26.8%
2021$117.14B+10.5%
2020$106.01B+4.0%
2019$101.93B+8.2%
2018$94.21B+0.2%
2017$94.06B-0.6%
2016$94.60B-